ADRIAMYCIN AND CISPLATIN FOR HEPATOBLASTOMA
ADRIAMYCIN AND CISPLATIN FOR HEPATOBLASTOMA
复制标题
DOI：
10.1002/1097-0142(19851015)56:8
复制
发表时间：
1985-01-01
期刊：
影响因子：
6.2
通讯作者：
FOSTER, JH
中科院分区：
文献类型：
--
作者：
QUINN, JJ;ALTMAN, AJ;FOSTER, JH
连续四名婴儿和儿童肝母细胞瘤用阿霉素(阿霉素)和顺铂联合治疗。三名患者有无法切除的肿瘤，每一名患者的肿瘤大小和血清甲胎蛋白(AFP)水平都显著下降。其中两名患者的肿瘤包括一名肺转移患者的肿瘤已清除，均可手术切除。第三位患者S肿瘤仍无法切除，但放射治疗后甲胎蛋白水平恢复正常。这三位患者均无瘤，两人均未转移，停药时间为9-24个月。第四位患者在胚胎肝母细胞瘤切除后接受了联合治疗，停药7个月后仍无病可治。所有患者均可耐受，其主要毒副作用是骨髓抑制和镁损耗。阿霉素和顺铂联合治疗这些患者非常有效，值得进一步试验，特别是对不能切除和转移性肝母细胞瘤。
Four consecutive infants and children with hepatoblastomas were treated with a combination of Adriamycin (doxorubicin) and cisplatin. Three patients had unresectable tumors and in each there was a dramatic decrease in tumor size and serum alpha-fetoprotein (AFP) levels. The tumors of two of these patients including one with pulmonary metastases which cleared, were rendered resectable. The third patient''s tumor remained unresectable but this AFP level returned to normal following radiotherapy. All three patients are disease-free, and both without metastases are off therapy from 9 to 24 months. A fourth child received the combination as adjuvant therapy following resection of an embryonal hepatoblastoma and he remains disease-free 7 months afer its discontinuation. Therapy was tolerable in all patients and its principal toxicities were myelosuppression and magnesium wasting. Adriamycin and cisplatin in combination were very effective in these patients and deserve further trials, especially in unresectable and metastatic hepatoblastomas.